The Acquisition values the entire issued and to be issued ordinary share capital of the Company at approximately $27.8 billion on a fully diluted basis and implies an enterprise value of approximately $28.3 billion.
a premium of approximately 19.7% to the closing price of $97.29 per Company Share on December 9, 2022.a premium of approximately 47.9% to the closing price of $78.76 per Company Share on Novem(being the last closing price per Company Share prior to the Company's issuance of an announcement of a possible offer under Rule 2.4 of the Irish Takeover Rules) and.Under the terms of the Acquisition, each Company Shareholder at the Scheme Record Time will be entitled to receive: (" Amgen") are pleased to announce that they have reached agreement on the terms of a cash offer for the Company by Pillartree Limited (" Acquirer Sub"), a newly formed private limited company wholly owned by Amgen, which is unanimously recommended by the Company Board and pursuant to which Acquirer Sub will acquire the entire issued and to be issued ordinary share capital of the Company. The board of directors of Horizon Therapeutics plc (the " Company" or " Horizon") and the board of directors of Amgen Inc.To be implemented by way of a scheme of arrangement under Chapter 1 of Part 9 of the Companies Act 2014 Pillartree Limited, a newly formed private limited company wholly owned by Amgen Inc. THIS ANNOUNCEMENT IS BEING MADE PURSUANT TO RULE 2.7 OF THE IRISH TAKEOVER RULES 12, 2022 /PRNewswire/ - NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION
Horizon therapeutics plc earnings trial#
Clinical Trial Diversity and RepresentationĬlinical Trial Transparency, Data Sharing and Disclosure PracticesĪdverse Event and Product Complaint ReportingĮnvironmental, Social & Governance Report 2021Įnvironment, Social and Governance StrategyĬommunity Investment and Amgen Foundation
0 kommentar(er)
